These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 19782440)

  • 21. FOG: Fragment Optimized Growth algorithm for the de novo generation of molecules occupying druglike chemical space.
    Kutchukian PS; Lou D; Shakhnovich EI
    J Chem Inf Model; 2009 Jul; 49(7):1630-42. PubMed ID: 19527020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Flexible 3D pharmacophores as descriptors of dynamic biological space.
    Nettles JH; Jenkins JL; Williams C; Clark AM; Bender A; Deng Z; Davies JW; Glick M
    J Mol Graph Model; 2007 Oct; 26(3):622-33. PubMed ID: 17395510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The properties of known drugs. 1. Molecular frameworks.
    Bemis GW; Murcko MA
    J Med Chem; 1996 Jul; 39(15):2887-93. PubMed ID: 8709122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular properties that influence oral drug-like behavior.
    Lajiness MS; Vieth M; Erickson J
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):470-7. PubMed ID: 15338956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Guiding molecules towards drug-likeness.
    Egan WJ; Walters WP; Murcko MA
    Curr Opin Drug Discov Devel; 2002 Jul; 5(4):540-9. PubMed ID: 12197312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry.
    Feher M; Schmidt JM
    J Chem Inf Comput Sci; 2003; 43(1):218-27. PubMed ID: 12546556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ultimate carcinogenic metabolites from aromatic and heterocyclic aromatic amines: a computational study in relation to their mutagenic potency.
    Borosky GL
    Chem Res Toxicol; 2007 Feb; 20(2):171-80. PubMed ID: 17261035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fragment-based activity space: smaller is better.
    Hesterkamp T; Whittaker M
    Curr Opin Chem Biol; 2008 Jun; 12(3):260-8. PubMed ID: 18316043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. "Bayes affinity fingerprints" improve retrieval rates in virtual screening and define orthogonal bioactivity space: when are multitarget drugs a feasible concept?
    Bender A; Jenkins JL; Glick M; Deng Z; Nettles JH; Davies JW
    J Chem Inf Model; 2006; 46(6):2445-56. PubMed ID: 17125186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In silico prediction of ionization constants of drugs.
    Lee PH; Ayyampalayam SN; Carreira LA; Shalaeva M; Bhattachar S; Coselmon R; Poole S; Gifford E; Lombardo F
    Mol Pharm; 2007; 4(4):498-512. PubMed ID: 17629304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hologram QSAR model for the prediction of human oral bioavailability.
    Moda TL; Montanari CA; Andricopulo AD
    Bioorg Med Chem; 2007 Dec; 15(24):7738-45. PubMed ID: 17870541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enumeration of 166 billion organic small molecules in the chemical universe database GDB-17.
    Ruddigkeit L; van Deursen R; Blum LC; Reymond JL
    J Chem Inf Model; 2012 Nov; 52(11):2864-75. PubMed ID: 23088335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Designing active template molecules by combining computational de novo design and human chemist's expertise.
    Lameijer EW; Tromp RA; Spanjersberg RF; Brussee J; Ijzerman AP
    J Med Chem; 2007 Apr; 50(8):1925-32. PubMed ID: 17367122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-based maximal affinity model predicts small-molecule druggability.
    Cheng AC; Coleman RG; Smyth KT; Cao Q; Soulard P; Caffrey DR; Salzberg AC; Huang ES
    Nat Biotechnol; 2007 Jan; 25(1):71-5. PubMed ID: 17211405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pursuing the leadlikeness concept in pharmaceutical research.
    Hann MM; Oprea TI
    Curr Opin Chem Biol; 2004 Jun; 8(3):255-63. PubMed ID: 15183323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and validation of in silico models for estimating drug preformulation risk in PEG400/water and Tween80/water systems.
    Crivori P; Morelli A; Pezzetta D; Rocchetti M; Poggesi I
    Eur J Pharm Sci; 2007 Nov; 32(3):169-81. PubMed ID: 17714921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In silico identification of bioisosteric functional groups.
    Ertl P
    Curr Opin Drug Discov Devel; 2007 May; 10(3):281-8. PubMed ID: 17554854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ring systems in mutagenicity databases.
    Kho R; Hodges JA; Hansen MR; Villar HO
    J Med Chem; 2005 Oct; 48(21):6671-8. PubMed ID: 16220983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enriching chemical space with diversity-oriented synthesis.
    Thomas GL; Wyatt EE; Spring DR
    Curr Opin Drug Discov Devel; 2006 Nov; 9(6):700-12. PubMed ID: 17117681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.